Cutamesine, an agonsit of brain sigma 1 receptors, was developed by Santen Pharmaceutical for the treatment of cognitive diseases. The drug was tested in phase II in patients with major depressive disorders and for recovery of patients with stroke, however its development was terminated for the given conditions. Currently M's science corporation is developing cutamesine for Amyotrophic lateral sclerosis and Retinitis pigmentosa as more suitable target diseases.

Revenast is an anti-allergic compound that is rapidly and extensively metabolized in animals. It is not acting as an anti-histaminic. Revenast has low bioavailability (reported in monkeys) and high protein binding (in humans). Information about current use of this compound is not available.

Galdansetron is a selective serotonin antagonist compound that is effective against vomiting and nausea. This type of drug is used to treat motion sickness or side effects of chemotherapy or anesthetics.

Rolziracetam (CI-911) is a nootropic drug. In several animal species (monkey, dogs, and rats) it was found to be rapidly eliminated from the body with a half-life of less than 25 min. Rolziracetam improved performance on a delayed-response task in aged rhesus monkeys. The drug was ineffective in a scopolamine-induced amnesia mouse model, in contrast to other nootropic drugs. Development of this piracetam-type cognitive enhancer was terminated.

Dimetamfetamine is the N-methylated analog of methamphetamine, produces behavioral effects that are generally comparable to those of methamphetamine, but with reduced potency. It is often found as an impurity in preparations of methamphetamine. Dimetamfetamine itself is less neurotoxic than methamphetamine. Dimetamfetamine is metabolized to p-hydroxyl methamphetamine, p-hydroxyl dimetamfetamine, amphetamine, methamphetamine, and N,N-dimethylamphetamine N-oxide in humans, and flavin-containing monooxygenase-1 and CYP2D6 are mainly involved in the N-oxidation and N-demethylation of dimetamfetamine, respectively. Dimetamfetamine has also been used illegally in Korea, and the Korean government placed DMA on the official list of controlled substances on December 4, 2006.

Dibuprol is a muscle relaxant and choleretic drug.

Priralfinamide, also known as Ralfinamide, FCE-26742A; NW-1029; PNU-0154339E, is a Na-channel blocker for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain. It has a relatively complex pharmacology, acting as a mixed voltage-gated sodium channel blocker (including Nav1.7), N-type calcium channel blocker, noncompetitive NMDA receptor antagonist, and monoamine oxidase B inhibitor. Priralfinamide is in phase Ⅲ clinical trials by Newron for the treatment of chronic neuropathic pain.

Schering published xanthine PDE5 inhibitors with amino substituents in the imidazole 2-position, such as Dasantafil. Dasantafil, also known as SCH-446132, is a PDE5A inhibitor potentially for the treatment of erectile dysfunction. It had been in phase II clinical trials but there is no report for this compound recently.

Loxoribine [RWJ 217C7] is an immunostimulant which was developed by Johnson and Johnson. It is a selective agonist for TLR7 (Toll-like receptor 7), which possesses antitumor and antiviral properties and was investigated in a rat model of endometriosis and in addition, in phase I of a clinical trial for patients with advanced cancer.